April 18th 2024
Researchers were unable to find a significant benefit for patients for the majority of cancer medications given accelerated FDA approval.
IRA is Expected to Cut Out-of-Pocket Costs by 28% for Women in Medicare
April 2nd 2024In 2025, the out-of-pocket cap and other Part D related provisions in the Inflation Reduction Act are projected to save women in Medicare an average of 28% in out-of-pocket costs, according to a new analysis from the Office of the Assistant Secretary for Planning and Evaluation.
Payers Question CMS’ Ability to Get Discounts Though Drug Price Negotiation
March 19th 2024In a recent survey, payers said the Inflation Reduction Act will help lower patients’ out-of-pocket costs, but they were concerned about Medicare’s drug price negotiation and the IRA’s impact on formulary management.
Michigan is First Medicaid Program to Offer Lyfgenia for Sickle Cell
March 11th 2024Michigan’s state Medicaid agency has signed an outcomes-based agreement for Lyfgenia patients with sickle cell disease. The agreement provides payers with risk sharing tied to vaso-occlusive events-related hospitalizations